Knight Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | GUD.TO | CA4990531069 | A1XE7A

날짜	Knight Therapeutics 주식 가격
	5.56 undefined
	5.63 undefined
	5.62 undefined
	5.62 undefined
	5.63 undefined
	5.63 undefined
	5.65 undefined
	5.57 undefined
	5.64 undefined
	5.70 undefined
	5.71 undefined
	5.72 undefined
	5.75 undefined
	5.73 undefined
	5.55 undefined
	5.46 undefined
	5.54 undefined
	5.77 undefined
	5.75 undefined
	5.75 undefined

날짜	Knight Therapeutics 매출	Knight Therapeutics EBIT	Knight Therapeutics 이익
2030e	571.89 백만 undefined	0 undefined	66 백만 undefined
2029e	517.92 백만 undefined	0 undefined	52.59 백만 undefined
2028e	478.76 백만 undefined	0 undefined	45.37 백만 undefined
2027e	434.61 백만 undefined	0 undefined	34.49 백만 undefined
2026e	403.52 백만 undefined	-2.75 백만 undefined	12.09 백만 undefined
2025e	363.29 백만 undefined	17.69 백만 undefined	8.26 백만 undefined
2024e	365.17 백만 undefined	11.01 백만 undefined	-5.04 백만 undefined
2023	328.2 백만 undefined	6.37 백만 undefined	-16.84 백만 undefined
2022	293.56 백만 undefined	-17.06 백만 undefined	-29.89 백만 undefined
2021	243.48 백만 undefined	-12.83 백만 undefined	15.68 백만 undefined
2020	199.5 백만 undefined	-26.3 백만 undefined	42.1 백만 undefined
2019	47.5 백만 undefined	-4.7 백만 undefined	14.5 백만 undefined
2018	12.5 백만 undefined	-5.8 백만 undefined	24.1 백만 undefined
2017	8.6 백만 undefined	-8.9 백만 undefined	17.2 백만 undefined
2016	5.9 백만 undefined	-3.9 백만 undefined	18.6 백만 undefined
2015	1 백만 undefined	-9.1 백만 undefined	34.2 백만 undefined
2014	400,000 undefined	-4.6 백만 undefined	125.9 백만 undefined

	매출	EBIT	이익
2014	400,000 CAD	-4.6 백만 CAD	125.9 백만 CAD
2015	1 백만 CAD	-9.1 백만 CAD	34.2 백만 CAD
2016	5.9 백만 CAD	-3.9 백만 CAD	18.6 백만 CAD
2017	8.6 백만 CAD	-8.9 백만 CAD	17.2 백만 CAD
2018	12.5 백만 CAD	-5.8 백만 CAD	24.1 백만 CAD
2019	47.5 백만 CAD	-4.7 백만 CAD	14.5 백만 CAD
2020	199.5 백만 CAD	-26.3 백만 CAD	42.1 백만 CAD
2021	243.48 백만 CAD	-12.83 백만 CAD	15.68 백만 CAD
2022	293.56 백만 CAD	-17.06 백만 CAD	-29.89 백만 CAD
2023	328.2 백만 CAD	6.37 백만 CAD	-16.84 백만 CAD
2024e	365.17 백만 CAD	11.01 백만 CAD	-5.04 백만 CAD
2025e	363.29 백만 CAD	17.69 백만 CAD	8.26 백만 CAD
2026e	403.52 백만 CAD	-2.75 백만 CAD	12.09 백만 CAD
2027e	434.61 백만 CAD	0 CAD	34.49 백만 CAD
2028e	478.76 백만 CAD	0 CAD	45.37 백만 CAD
2029e	517.92 백만 CAD	0 CAD	52.59 백만 CAD
2030e	571.89 백만 CAD	0 CAD	66 백만 CAD

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0	1	5	8	12	47	199	243	293	328	365	363	403	434	478	517	571
-	-	400.00	60.00	50.00	291.67	323.40	22.11	20.58	11.95	11.28	-0.55	11.02	7.69	10.14	8.16	10.44
-	15,200.00	80.00	87.50	83.33	55.32	40.70	47.33	47.10	46.34	41.64	41.87	37.72	35.02	31.80	29.40	26.62
0	0	4	7	10	26	81	115	138	152	0	0	0	0	0	0	0
125	34	18	17	24	14	42	15	-29	-16	-5	8	12	34	45	52	65
-	-72.80	-47.06	-5.56	41.18	-41.67	200.00	-64.29	-293.33	-44.83	-68.75	-260.00	50.00	183.33	32.35	15.56	25.00
57.3	96.5	121.3	143.4	143.3	140.1	132	124.52	114.89	107.47	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

426.9	494.8	787.8	787.9	703.8	427.7	411.2	162.7	191.04	157.83
0.1	0.4	2.6	2.1	2.9	103.5	62.5	55.39	94.89	88.72
0.9	2.4	7.9	6.8	8.6	8.2	19.5	12.03	15.32	21.54
0.6	1.5	0.8	1.2	1.1	70.9	56.5	72.4	92.49	91.83
0	0.4	0.6	1.1	1	11.2	2.4	2.45	1.88	5.18
428.5	499.5	799.7	799.1	717.4	621.5	552.1	304.97	395.62	365.12
0	0	0	0.6	0.8	29	26.2	29.94	22.63	17.86
19.9	106.6	170.8	189	289.7	260	175.1	179.41	156.09	116.36
35.7	32.3	0	0	23.3	46.3	41.7	43.43	43.85	49.2
0.8	3.3	14.2	12.6	17.5	173.4	156.5	350.3	338.78	289.96
0	0	0	0	0	88.3	77.7	75.4	82.27	79.84
1.6	7.2	6.1	4.7	3	86.8	10.3	8.44	15.6	27.16
58	149.4	191.1	206.9	334.3	683.8	487.5	686.92	659.22	580.38
0.49	0.65	0.99	1.01	1.05	1.31	1.04	0.99	1.05	0.95

341.1	439.1	760.4	761.5	761.8	723.8	694.4	628.85	599.06	540.05
2.1	6.8	9.5	12.2	14.3	16.5	18.7	21.78	23.66	25.99
125.9	160.2	179.4	196.6	232.9	53	174.7	191.76	161.87	151.01
3.2	22.1	15.4	1.1	33.2	25.9	7	7.86	49.39	38.24
6.8	13.9	15	19.9	-12.2	-8.4	-8.5	-8.24	-8.13	-8.41
0.48	0.64	0.98	0.99	1.03	0.81	0.89	0.84	0.83	0.75
0.6	0	0.7	0.5	0.8	72.8	44.5	65.31	106.06	85.37
1.5	2.4	2.5	4.5	5.3	21.6	0	0	0	0
5.5	4.3	6.6	9.2	11.1	204.1	15.9	11.72	15.01	9.09
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	52.3	53.6	28.28	20.25	19.58
7.6	6.7	9.8	14.2	17.2	350.8	114	105.3	141.32	114.03
0	0	0	0	0	9.8	2.5	12.68	57.45	49.51
0	0.2	0	0	0	27.9	21.6	12.37	4.37	2.82
0	0	1.3	0.5	4.6	1.7	15.2	19.52	25.85	32.26
0	0.2	1.3	0.5	4.6	39.4	39.3	44.57	87.66	84.59
7.6	6.9	11.1	14.7	21.8	390.2	153.3	149.87	228.98	198.62
0.49	0.65	0.99	1.01	1.05	1.2	1.04	0.99	1.05	0.95

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
125	34	18	17	24	18	31	15	-29	-16
0	0	0	1	1	4	32	47	62	50
0	0	0	2	1	0	-2	-7	-17	-9
4	-3	1	8	-23	-10	-23	-2	-8	-26
-130	-23	-6	-5	-10	-8	-50	-9	37	38
0	0	0	0	0	2	1	2	4	9
0	1	7	3	0	2	6	8	5	5
0	7	14	23	-5	4	-12	44	45	35
0	-1	-9	0	-3	-2	-20	-224	-25	-9
-49	-67	-49	-39	-252	-11	101	-105	-63	29
-49	-65	-39	-39	-248	-8	122	118	-37	39
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	-8	6	-14	31	-18
328	13	313	0	0	-54	-36	-64	-30	-53
328	13	313	0	0	-62	-29	-78	-2	-81
-	-	-	-	-	-	-	-	-4.00	-9.00
0	0	0	0	0	0	0	0	0	0
283	-45	277	-18	-251	-70	55	-143	-14	-12
0.73	5.89	4.88	23.33	-9.61	1.65	-32.88	-179.57	19.18	25.98
0	0	0	0	0	0	0	0	0	0

Knight Therapeutics 브루토마진	Knight Therapeutics 이익 마진	Knight Therapeutics EBIT-마진	Knight Therapeutics 이익 마진
2030e	46.51 %	0 %	11.54 %
2029e	46.51 %	0 %	10.15 %
2028e	46.51 %	0 %	9.48 %
2027e	46.51 %	0 %	7.93 %
2026e	46.51 %	-0.68 %	3 %
2025e	46.51 %	4.87 %	2.27 %
2024e	46.51 %	3.01 %	-1.38 %
2023	46.51 %	1.94 %	-5.13 %
2022	47.03 %	-5.81 %	-10.18 %
2021	47.4 %	-5.27 %	6.44 %
2020	40.95 %	-13.18 %	21.1 %
2019	56.63 %	-9.89 %	30.53 %
2018	82.4 %	-46.4 %	192.8 %
2017	81.4 %	-103.49 %	200 %
2016	74.58 %	-66.1 %	315.25 %
2015	60 %	-910 %	3,420 %
2014	46.51 %	-1,150 %	31,475 %

	브루토마진	EBIT-마진	이익 마진
2014	46.51 %	-1,150 %	31,475 %
2015	60 %	-910 %	3,420 %
2016	74.58 %	-66.1 %	315.25 %
2017	81.4 %	-103.49 %	200 %
2018	82.4 %	-46.4 %	192.8 %
2019	56.63 %	-9.89 %	30.53 %
2020	40.95 %	-13.18 %	21.1 %
2021	47.4 %	-5.27 %	6.44 %
2022	47.03 %	-5.81 %	-10.18 %
2023	46.51 %	1.94 %	-5.13 %
2024e	46.51 %	3.01 %	-1.38 %
2025e	46.51 %	4.87 %	2.27 %
2026e	46.51 %	-0.68 %	3 %
2027e	46.51 %	0 %	7.93 %
2028e	46.51 %	0 %	9.48 %
2029e	46.51 %	0 %	10.15 %
2030e	46.51 %	0 %	11.54 %

날짜	Knight Therapeutics 주당 매출	Knight Therapeutics EBIT 당 주식	Knight Therapeutics 주당 이익
2030e	5.73 undefined	0 undefined	0.66 undefined
2029e	5.19 undefined	0 undefined	0.53 undefined
2028e	4.8 undefined	0 undefined	0.46 undefined
2027e	4.36 undefined	0 undefined	0.35 undefined
2026e	4.05 undefined	0 undefined	0.12 undefined
2025e	3.64 undefined	0 undefined	0.08 undefined
2024e	3.66 undefined	0 undefined	-0.05 undefined
2023	3.05 undefined	0.06 undefined	-0.16 undefined
2022	2.56 undefined	-0.15 undefined	-0.26 undefined
2021	1.96 undefined	-0.1 undefined	0.13 undefined
2020	1.51 undefined	-0.2 undefined	0.32 undefined
2019	0.34 undefined	-0.03 undefined	0.1 undefined
2018	0.09 undefined	-0.04 undefined	0.17 undefined
2017	0.06 undefined	-0.06 undefined	0.12 undefined
2016	0.05 undefined	-0.03 undefined	0.15 undefined
2015	0.01 undefined	-0.09 undefined	0.35 undefined
2014	0.01 undefined	-0.08 undefined	2.2 undefined

	주당 매출	EBIT 당 주식	주당 이익
2014	0.01 CAD	-0.08 CAD	2.2 CAD
2015	0.01 CAD	-0.09 CAD	0.35 CAD
2016	0.05 CAD	-0.03 CAD	0.15 CAD
2017	0.06 CAD	-0.06 CAD	0.12 CAD
2018	0.09 CAD	-0.04 CAD	0.17 CAD
2019	0.34 CAD	-0.03 CAD	0.1 CAD
2020	1.51 CAD	-0.2 CAD	0.32 CAD
2021	1.96 CAD	-0.1 CAD	0.13 CAD
2022	2.56 CAD	-0.15 CAD	-0.26 CAD
2023	3.05 CAD	0.06 CAD	-0.16 CAD
2024e	3.66 CAD	0 CAD	-0.05 CAD
2025e	3.64 CAD	0 CAD	0.08 CAD
2026e	4.05 CAD	0 CAD	0.12 CAD
2027e	4.36 CAD	0 CAD	0.35 CAD
2028e	4.8 CAD	0 CAD	0.46 CAD
2029e	5.19 CAD	0 CAD	0.53 CAD
2030e	5.73 CAD	0 CAD	0.66 CAD

	주식 수량
2014	57.3 백만 Aktien
2015	96.5 백만 Aktien
2016	121.3 백만 Aktien
2017	143.4 백만 Aktien
2018	143.3 백만 Aktien
2019	140.1 백만 Aktien
2020	132 백만 Aktien
2021	124.52 백만 Aktien
2022	114.89 백만 Aktien
2023	107.47 백만 Aktien
2024e	107.47 백만 Aktien
2025e	107.47 백만 Aktien
2026e	107.47 백만 Aktien
2027e	107.47 백만 Aktien
2028e	107.47 백만 Aktien
2029e	107.47 백만 Aktien
2030e	107.47 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
0.02	0 (-100 %)	2024 Q3
0.02	-0.02 (-199.01 %)	2024 Q2
0.01	-0.04 (-697.01 %)	2024 Q1
-0.02	-0.23 (-1,163.74 %)	2023 Q4
-0.04	0.09 (305.48 %)	2023 Q3
-0.01	0.02 (258.73 %)	2023 Q2
-0.06	-0.04 (37.5 %)	2023 Q1
-0.08	-0.13 (-54.39 %)	2022 Q4
-0.05	0.01 (121.98 %)	2022 Q3
-0.02	0.02 (190.09 %)	2022 Q2
-0.04	-0.16 (-296.04 %)	2022 Q1
-0	-0.07 (-4,017.65 %)	2021 Q4
0.02	-0.07 (-516.67 %)	2021 Q3
-0.07	0.23 (410.39 %)	2021 Q2
-0.02	0.03 (248.51 %)	2021 Q1
0.01	0.06 (775 %)	2020 Q4
0	0.14 (3,400 %)	2020 Q3
-0.03	0.13 (613.83 %)	2020 Q2
-0.06	-0.01 (82.33 %)	2020 Q1
0.01	-0.05 (-488.89 %)	2019 Q4
0.03	-0.02 (-176.05 %)	2019 Q3
0.02	0.13 (516.82 %)	2019 Q2
0.03	0.04 (26.98 %)	2019 Q1
0.03	0 (-100 %)	2018 Q4
0.02	0.09 (310.96 %)	2018 Q3
0.03	0.03 (10.67 %)	2018 Q2
0.04	0.05 (37.36 %)	2018 Q1
0.04	0.05 (31.93 %)	2017 Q4
0.03	0.03 (11.52 %)	2017 Q3
0.04	0 (-91.53 %)	2017 Q2
0.03	0.04 (37.93 %)	2017 Q1
0.04	0.06 (57.89 %)	2016 Q4
0.03	0.04 (18.69 %)	2016 Q3
0.03	0.04 (32.01 %)	2016 Q2
0.03	0.01 (-83.5 %)	2016 Q1
0.03	0.05 (97.63 %)	2015 Q4
0	0.07 (0 %)	2015 Q3
-0.02	0.07 (560.53 %)	2015 Q2
0	0.01 (0 %)	2015 Q1
-0.01	-0.02 (-292.16 %)	2014 Q4
0	0 (0 %)	2014 Q3
-0.01	0.01 (296.08 %)	2014 Q2

%-지분	이름	주식	변경
20.81903 %	Long Zone Holdings, Inc.	20,760,733	-918,000
12.30004 %	G2S2 Capital Inc	12,265,600	1,064,300
11.53915 %	Medici Strategic Portfolio Management Inc	11,506,844	11,506,844
6.24106 %	QV Investors Inc.	6,223,584	0
1.08913 %	Dimensional Fund Advisors, L.P.	1,086,077	18,200
1.00568 %	Goodman (Jonathan Ross)	1,002,867	6,196
0.81808 %	DFA Australia Ltd.	815,792	-2
0.70197 %	Fidelity Investments Canada ULC	700,000	-457,100
0.41218 %	Bessemer Trust Company, N.A. (US)	411,025	0
0.39811 %	North Growth Management Ltd.	397,000	0
0.25621 %	Sakhia (Samira)	255,490	3,204
0.25213 %	CI Global Asset Management	251,423	0
0.24386 %	Lande (Robert N)	243,178	-25,000
0.23767 %	Royce Investment Partners	237,000	0
0.22453 %	Dimensional Fund Advisors, Ltd.	223,897	0
0.22181 %	Tredje AP Fonden	221,189	0
0.19782 %	BlackRock Advisors (UK) Limited	197,267	2,655
0.19044 %	Jarislowsky Fraser, Ltd.	189,911	-21,089
0.16684 %	California State Teachers Retirement System	166,374	84,076
0.16629 %	BlackRock Institutional Trust Company, N.A.	165,820	-5,255
0.15527 %	Khouri, Amal	154,835	0
0.15433 %	Foyston, Gordon & Payne Inc.	153,900	0
0.10256 %	British Columbia Investment Management Corp.	102,274	-20,332
0.10028 %	NFS Netfonds Financial Service GmbH	100,000	0
0.09854 %	State Street Global Advisors (US)	98,267	-1,076
0.09005 %	Louisbourg Investments Inc.	89,800	0
0.07960 %	Brandes Investment Partners, L.P.	79,374	0
0.05568 %	Nuveen LLC	55,523	0
0.05484 %	Florida State Board of Administration	54,683	35,293
0.05255 %	Gale (James C)	52,406	1,353
0.04091 %	The Vanguard Group, Inc.	40,798	0
0.04087 %	Utchanah (Arvind)	40,756	1,620
0.04069 %	LSV Asset Management	40,574	-7,826
0.03651 %	Mercer Global Investments Management Ltd	36,410	0
0.03467 %	UBS Fund Management (Switzerland) AG	34,569	0
0.02646 %	UBS Asset Management (UK) Ltd.	26,386	0
0.02303 %	Northern Trust Global Investments Limited	22,961	0
0.02292 %	State Street Global Advisors Ireland Limited	22,855	0
0.02281 %	American Century Investment Management, Inc.	22,746	0
0.01940 %	Emblem (Susan Caroline)	19,348	1,386
0.01917 %	SEI Investments Canada	19,117	0
0.01903 %	Vanguard Investments Australia Ltd.	18,978	13
0.01603 %	BlackRock Investment Management (UK) Ltd.	15,983	0
0.01374 %	KLP Fondsforvaltning AS	13,700	0
0.01363 %	Manulife Investment Management (North America) Limited	13,588	1,788
0.01317 %	Z¿rcher Kantonalbank (Asset Management)	13,131	-9,587
0.01188 %	1832 Asset Management L.P.	11,846	0
0.01183 %	Sujoy (Nicolás)	11,800	-5,310
0.01073 %	Acadian Asset Management LLC	10,700	10,700
0.00980 %	Laurus Investment Counsel	9,769	-14,261
0.00855 %	MLC Asset Management	8,528	6,956
0.00852 %	Murray (Janice Jean)	8,493	-4,815
0.00802 %	Evli Fund Management Company Ltd.	8,000	0
0.00572 %	Pictet Asset Management Ltd.	5,700	0
0.00534 %	Legal & General Investment Management Ltd.	5,329	0
0.00491 %	UBS Asset Management (Switzerland)	4,900	0
0.00441 %	Percario (Monica Barbanti Cabral de Vasconcellos)	4,397	4,397
0.00361 %	Connor, Clark & Lunn Investment Management Ltd.	3,600	0
0.00306 %	Groleau (Melanie)	3,053	3,053
0.00262 %	AllianceBernstein L.P.	2,614	0
0.00211 %	Dos Santos Dias (Henrique Jose)	2,106	503
0.00201 %	Tremblay (Michael Joseph)	2,000	-5,310
0.00088 %	Montejo (Ricardo Adolfo)	873	466
0.00072 %	Lopez (German)	720	720
0.00016 %	MLC Investments Limited	158	158
0 %	Man Investments Inc	0	-11
0 %	Man Investments, Ltd.	0	-5
0 %	Gesiuris Asset Management S.G.I.I.C., S.A.	0	-75,641
0 %	Geode Capital Management, L.L.C.	0	-44,174
0 %	BlackRock Asset Management Canada Limited	0	-154
0 %	Russell Investments Limited	0	-4,593
0 %	Boston Partners	0	-8,833
0 %	Artisan Partners Limited Partnership	0	-286,651
0 %	HSBC Global Asset Management (UK) Limited	0	-175
0 %	Fidelity International	0	-179
0 %	Handelsbanken Kapitalf¿rvaltning AB	0	-35,700
0 %	CIBC Asset Management Inc.	0	-47,900
0 %	Desjardins Global Asset Management	0	-74,611
0 %	Fidelity Management & Research Company LLC	0	-1,024

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Profound Medical	공급업체고객	0,76	0,34	0,35	-0,28	-0,32	0,05
Synergy CHC	공급업체고객	0,43		0,09	0,10
AstraZeneca	공급업체고객	0,42	-0,06	-0,53		0,14	0,09
Titan Pharmaceuticals	공급업체고객	0,35	-0,07	0,42	-0,08	-0,32	0,91
Jaguar Health	공급업체고객	0,30	0,09	-0,04	-0,40	-0,37	-0,22
Biotoscana Investments S.A.	공급업체고객	0,23		0,29	-0,39	-0,26	-0,60
Advaxis	공급업체고객	0,18	-0,04	0,31	-0,38	-0,39	0,19
Onconova Therapeutics	공급업체고객	0,13	-0,15	-0,10	-0,46	-0,36	0,30
Antibe Therapeutics	공급업체고객	0,11	0,06	-0,27	0,01	-0,32	0,33
Alimera Sciences	공급업체고객	0,10		-0,39	-0,13	-0,35	-0,15

What values and corporate philosophy does Knight Therapeutics represent?

Knight Therapeutics Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on delivering innovative pharmaceutical solutions, Knight Therapeutics is committed to improving patient outcomes and making a positive impact on global health. The company prioritizes ethical business practices, ensuring transparency and reliability in all its operations. Knight Therapeutics Inc emphasizes building strong partnerships with healthcare professionals and stakeholders to achieve shared goals. By consistently upholding its values and corporate philosophy, Knight Therapeutics Inc strives to be a trusted leader in the pharmaceutical industry.

In which countries and regions is Knight Therapeutics primarily present?

Knight Therapeutics Inc is primarily present in Canada, where it is headquartered in Quebec. As a specialty pharmaceutical company, Knight Therapeutics focuses on acquiring, developing, and commercializing innovative prescription drugs. With a strategic focus on Canada, the company also operates in other regions, including the United States and select European countries. As Knight Therapeutics continues to expand its presence and partnerships in the pharmaceutical industry, it aims to bring innovative therapies to patients worldwide.

What significant milestones has the company Knight Therapeutics achieved?

Some significant milestones achieved by Knight Therapeutics Inc include expanding its product portfolio through strategic licensing agreements, successfully completing several clinical trials, and securing regulatory approvals for its pharmaceutical products in various markets. The company has also demonstrated strong financial performance, achieving consistent revenue growth and generating positive cash flow. Knight Therapeutics Inc has established partnerships with world-class pharmaceutical companies to leverage their expertise and expand its global reach. Furthermore, the company has made notable progress in advancing its pipeline of innovative therapies, aimed at addressing unmet medical needs and improving patient outcomes.

What is the history and background of the company Knight Therapeutics?

Knight Therapeutics Inc. is a leading Canadian specialty pharmaceutical company established in 2014. Headquartered in Montreal, Quebec, Knight focuses on acquiring and commercializing innovative pharmaceutical products for the Canadian and international markets. With a mission to improve patient care by providing novel treatment options, Knight Therapeutics collaborates with global partners to bring cutting-edge therapies to market. The company's portfolio includes a diverse range of therapeutic areas such as oncology, mental health, and rare diseases. Known for its strategic management and growth-oriented approach, Knight Therapeutics is committed to delivering high-quality pharmaceuticals that address unmet medical needs and enhance healthcare outcomes.

Who are the main competitors of Knight Therapeutics in the market?

The main competitors of Knight Therapeutics Inc in the market include other pharmaceutical companies such as Valeo Pharma Inc, Cipher Pharmaceuticals Inc, and Crescita Therapeutics Inc.

In which industries is Knight Therapeutics primarily active?

Knight Therapeutics Inc is primarily active in the pharmaceutical industry. As a Canadian specialty pharmaceutical company, Knight Therapeutics focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and international markets. With a diverse portfolio, the company primarily operates in areas such as intellectual property-protected medicines, biotechnology products, and specialty pharmaceuticals. Knight Therapeutics strives to collaborate with global partners to bring novel therapies to patients, contributing to improved healthcare outcomes. Through its activities in the pharmaceutical industry, Knight Therapeutics aims to address unmet medical needs and provide innovative solutions for patients worldwide.

What is the business model of Knight Therapeutics?

The business model of Knight Therapeutics Inc. is focused on acquiring or in-licensing innovative pharmaceutical products and commercializing them in Canada and other global markets. Knight's strategy involves partnering with established pharmaceutical companies or academic institutions to access a diverse range of therapeutics and medical devices. By focusing on products that are either proven or have a high probability of regulatory approval, Knight aims to bring innovative treatments to patients and generate sustainable revenue growth. With its expertise in regulatory affairs, marketing, and distribution, Knight Therapeutics Inc. aims to optimize the value of its portfolio and deliver long-term value to shareholders.

Knight Therapeutics 2025의 P/E 비율은 얼마입니까?

Knight Therapeutics의 P/E 비율은 72.35입니다.

Knight Therapeutics 2025의 KUV는 얼마입니까?

Knight Therapeutics의 P/S 비율은 1.64입니다.

Knight Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

Knight Therapeutics에 대한 AlleAktien 품질 점수는 3/10입니다.

Knight Therapeutics 2025의 매출은 얼마인가요?

예상되는 Knight Therapeutics 매출은 363.29 백만 CAD입니다.

Knight Therapeutics 2025의 이익은 얼마인가요?

예상되는 Knight Therapeutics 이익은 8.26 백만 CAD입니다.

Knight Therapeutics은 무엇을 하나요?

Knight Therapeutics Inc is a Canadian biopharmaceutical company that specializes in the development and marketing of innovative medicines. The company focuses on five main areas: infectious diseases, pain management, oncology, ophthalmology, and neuropsychiatric disorders. It works closely with leading research institutes and companies to find innovative approaches for these diseases and improve treatment options. Knight Therapeutics offers medication for life-threatening infections such as HIV, hepatitis, and tuberculosis, as well as tailored pain medications. It also develops therapies for cancer treatment, eye diseases, and neuropsychiatric disorders. Overall, Knight Therapeutics specializes in developing and marketing innovative medicines, working with research institutes and having a strong presence in the North American market. Its goal is to improve the lives of millions of people worldwide and contribute to medical research and development.

Knight Therapeutics 배당금은 얼마입니까?

Knight Therapeutics은(는) 연간 번의 배당을 통해 0 CAD의 배당금을 지급합니다.

Knight Therapeutics이 얼마나 자주 배당을 지급하나요?

Knight Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Knight Therapeutics ISIN이 무엇입니까?

Knight Therapeutics의 ISIN은 CA4990531069입니다.

Knight Therapeutics WKN은 무엇인가요?

Knight Therapeutics의 WKN은 A1XE7A입니다.

Knight Therapeutics 티커는 무엇인가요?

Knight Therapeutics의 티커는 GUD.TO입니다.

Knight Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Knight Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Knight Therapeutics은(는) 0 CAD의 배당금을 지급할 것으로 예상됩니다.

Knight Therapeutics의 배당 수익률은 얼마입니까?

Knight Therapeutics의 현재 배당 수익률은 입니다.

Knight Therapeutics의 배당금은 언제 지급되나요?

Knight Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Knight Therapeutics의 배당금은 얼마나 안전한가요?

Knight Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Knight Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 CAD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Knight Therapeutics이(가) 속해 있는 섹터는 어디인가요?

Knight Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Knight Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Knight Therapeutics의 마지막 배당금을 0 CAD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Knight Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Knight Therapeutics의 2024년도 배당금은 얼마였습니까?

2024년에 Knight Therapeutics는 0 CAD를 배당금으로 지급했습니다.

Knight Therapeutics는 어떤 화폐로 배당금을 지급하나요?

Knight Therapeutics의 배당금은 CAD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	Knight Therapeutics 티커
프랑크푸르트	04K.F
뮌헨	04K.MU
PNK	KHTRF
TSX	GUD.TO

Knight Therapeutics 티커	Knight Therapeutics FIGI
GUD:CN	BBG006373G44
GUD:CT	BBG006373G71
GUD:CJ	BBG006373GD4
GUD:TR	BBG006373GG1
GUD:TX	BBG006373GJ8
GUD:TA	BBG006373GK6
GUD:TG	BBG006373GM4
GUD:TK	BBG006373GN3
GUD:TW	BBG006373GP1
GUD:DT	BBG006373GV4
GUD:DG	BBG006373GW3
KHTRF:US	BBG0068Q74Y7
KHTRF:PQ	BBG0068Q75C8
KHTRF:UV	BBG0068Q75F5
04K:GR	BBG006FYQR16
04K:GF	BBG006FYQR25
04K:GM	BBG006FYQR61
GUDEUR:EO	BBG006G0R856
GUDEUR:XH	BBG006G0R883
GUDEUR:XF	BBG006G0R8B9
GUDEUR:XE	BBG006G0R8D7
GUDEUR:XJ	BBG006G0R8F5
GUDEUR:XL	BBG006G0R8G4
GUDEUR:XG	BBG006G0R8H3
GUDEUR:XO	BBG006G0R8J1
GUDEUR:XS	BBG006G0R8N6
GUDEUR:XA	BBG006G0R8P4
GUDEUR:E1	BBG006G0R8Q3
GUDEUR:XT	BBG006G0R8R2
GUDEUR:XW	BBG006G0R8S1
GUDEUR:XU	BBG006G0R8T0
GUDEUR:XV	BBG006G0R8W6
GUDEUR:EU	BBG006G0R8Z3
GUD:QF	BBG0086KMRY0
GUD:QH	BBG0086KMRZ9
GUD:DJ	BBG00DVMR909
GUDEUR:XX	BBG00JN86RR0
GUDCAD:X2	BBG00JVL55J0
GUDCAD:XB	BBG00JVL55K8
GUDCAD:XH	BBG00JVL55M6
GUDCAD:XF	BBG00JVL55P3
GUDCAD:XE	BBG00JVL55R1
GUDCAD:XJ	BBG00JVL55S0
GUDCAD:XL	BBG00JVL55T9
GUDCAD:XG	BBG00JVL55V6
GUDCAD:XO	BBG00JVL55W5
GUDCAD:XS	BBG00JVL5608
GUDCAD:XA	BBG00JVL5617
GUDCAD:E1	BBG00JVL5626
GUDCAD:XT	BBG00JVL5635
GUDCAD:XW	BBG00JVL5644
GUDCAD:XU	BBG00JVL5653
GUDCAD:XV	BBG00JVL5662
GUDCAD:XM	BBG00JVL5671
GUDCAD:XQ	BBG00JVL5699
GUDCAD:XX	BBG00JVL56B6
GUDCAD:XZ	BBG00JVL56C5
GUDCAD:EU	BBG00JVL56F2
GUDGBP:XS	BBG00KVYGD91
GUDGBP:XH	BBG00KVYGDD6
GUDGBP:XF	BBG00KVYGDG3
GUDGBP:XE	BBG00KVYGDJ0
GUDGBP:XJ	BBG00KVYGDK8
GUDGBP:XL	BBG00KVYGDL7
GUDGBP:XG	BBG00KVYGDM6
GUDGBP:XO	BBG00KVYGDN5
GUDGBP:XA	BBG00KVYGDS0
GUDGBP:E1	BBG00KVYGDT9
GUDGBP:XT	BBG00KVYGDV6
GUDGBP:XW	BBG00KVYGDW5
GUDGBP:XU	BBG00KVYGDX4
GUDGBP:XV	BBG00KVYGDY3
GUDGBP:XM	BBG00KVYGDZ2
GUDGBP:XQ	BBG00KVYGF14
GUDGBP:XX	BBG00KVYGF23
GUDGBP:XZ	BBG00KVYGF32
GUDGBP:EU	BBG00KVYGF50
GUD:QG	BBG00LN9MHN1
04K:TH	BBG00P4J0BF7
GUDEUR:EP	BBG00T85BTV6
GUDEUR:EZ	BBG00T85BTX4
GUDCAD:EP	BBG00TD1CND1
GUDCAD:EZ	BBG00TD1CNH7
04K:LA	BBG018H9BKC3
04K:LU	BBG018J2ZL47
GUD:BF	BBG019LPL818
04K:GZ	BBG01GM7F293
GUD:HD	BBG01J14S7Z3
GUD:HX	BBG01J15HJX8

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커GUD.TO

ISINCA4990531069

WKNA1XE7A

Knight Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Knight Therapeutics 주가 이력

Knight Therapeutics 주식 매출, EBIT, 이익 CA4990531069 · A1XE7A

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Knight Therapeutics 매출, 이익 및 EBIT 역사

Knight Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Knight Therapeutics 주식 마진 CA4990531069 · A1XE7A

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Knight Therapeutics 마진 역사

Knight Therapeutics 주식 매출, EBIT, 주당 순이익 CA4990531069 · A1XE7A

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Knight Therapeutics 매출, 이익 및 EBIT 주당 역사

Knight Therapeutics 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Knight Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Knight Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Knight Therapeutics 주식 수량 CA4990531069 · A1XE7A

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Knight Therapeutics 수익 예상

Knight Therapeutics 수익 놀라움

Eulerpool ESG Scorecard© Knight Therapeutics 주식을 위해

Eulerpool World ESG Rating (EESG©)

26/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

티커
GUD.TO

ISIN
CA4990531069

WKN
A1XE7A